ATC Group: L03AA Colony stimulating factors

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L03AA in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L03 Immunostimulants
3 L03A Immunostimulants
4 L03AA Colony stimulating factors

Group L03AA contents

Code Title
L03AA02 Filgrastim
L03AA03 Molgramostim
L03AA09 Sargramostim
L03AA10 Lenograstim
L03AA12 Ancestim
L03AA13 Pegfilgrastim
L03AA14
L03AA15
L03AA18
L03AA19

Active ingredients in L03AA

Active Ingredient Description
Efbemalenograstim alfa

Human granulocyte-colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Efbemalenograstim alfa is a recombinant fusion protein containing G-CSF, a 16 amino-acid linker, and the Fc portion of human IgG2. Efbemalenograstim alfa is a sustained duration form of G-CSF due to decreased renal clearance. Efbemalenograstim alfa and other G-CSFs have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.

Eflapegrastim

Eflapegrastim-xnst is a recombinant human granulocyte growth factor that binds to G-CSF receptors on myeloid progenitor cells and neutrophils, triggering signaling pathways that control cell differentiation, proliferation, migration and survival. Eflapegrastim-xnst has been shown to elevate neutrophil counts in healthy subjects and in cancer patients.

Filgrastim

Filgrastim causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.

Lenograstim

Lenograstim belongs to the cytokine group of biologically active proteins which regulate cell differentiation and cell growth. Lenograstim induces a marked increase in peripheral blood neutrophil counts within 24 hours of administration.

Lipegfilgrastim

Lipegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Lipegfilgrastim binds to human the G-CSF receptor like filgrastim and pegfilgrastim. Human G-CSF is a glycoprotein that regulates the production and release of functional neutrophils from the bone marrow.

Molgramostim
Pegfilgrastim

Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.

Sargramostim

Sargramostim is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways which include neutrophils, monocytes/macrophages and myeloid-derived dendritic cells.

Related product monographs

Title Information Source Document Type  
ACCOFIL Solution for injection / infusion European Medicines Agency (EU) MPI, EU: SmPC
FULPHILA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
GRANOCYTE Powder and solvent for solution for injection/infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
LONQUEX Solution for injection in pre-filled syringe European Medicines Agency (EU) MPI, EU: SmPC
NEULASTIM Solution for injection Health Products Regulatory Authority (ZA) MPI, Generic
NEUPOGEN Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
NIVESTYM Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
NYVEPRIA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
PELMEG Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
RATIOGRASTIM Solution for injection or infusion European Medicines Agency (EU) MPI, EU: SmPC
ROLVEDON Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
RYZNEUTA Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
RYZNEUTA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
STIMUFEND Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
UDENYCA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
ZARZIO Solution for injection / infusion European Medicines Agency (EU) MPI, EU: SmPC